UC Irvine

UC Irvine Previously Published Works

Title

Comparison of Perioperative Outcomes for Radical Nephrectomy Based on Surgical Approach for Masses Greater Than 10 cm.

Permalink

<https://escholarship.org/uc/item/2zg6g0s1>

Journal

Journal of endourology, 35(12)

ISSN

0892-7790

Authors

Grimaud, Logan W
Chen, Felix V
Chang, Jenny
[et al.](#)

Publication Date

2021-12-01

DOI

10.1089/end.2020.1164

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Comparison of Perioperative Outcomes for Radical Nephrectomy Based on Surgical Approach for Masses Greater Than 10 cm

Logan W. Grimaud, BS,^{1,i} Felix V. Chen, MD,¹ Jenny Chang, MPH,^{2,ii}
Argyrios Ziogas, PhD,² John P. Sfakianos, MD,³ Ketan K. Badani, MD,³ Edward M. Uchio, MD,¹
Hoda Anton-Culver, PhD,² and Greg E. Gin, MD, MS^{1,iii}

Abstract

Introduction and Objective: Robot-assisted radical nephrectomy (RRN) is increasingly utilized as an alternative to laparoscopic radical nephrectomy (LRN), but there are concerns over costs and objective benefit. In the setting of very large renal masses (>10 cm), comparison between techniques is limited and it is unclear whether a robotic approach confers any perioperative benefit over LRN or open radical nephrectomy (ORN). In this study, perioperative outcomes of RRN, LRN, and ORN for very large renal masses are compared.

Methods: Using the National Cancer Database, patients were identified who underwent radical nephrectomy for kidney tumors >10 cm diagnosed from 2010 to 2015. Patients were analyzed according to surgical approach. Perioperative outcomes, including conversion to open, length of stay, readmission rates, positive surgical margins, and 30- and 90-day mortality were compared among cohorts.

Results: A total of 9288 patients met inclusion criteria (RRN = 842, LRN = 2326, ORN = 6120). Compared with ORN, recipients of RRN or LRN had similar rates of 30-day readmission and 30- and 90-day mortality. Length of hospital stay was significantly shorter in RRN (−1.73 days ±0.19; $p < 0.0001$) and LRN (−1.40 days ±0.12; $p < 0.0001$) compared with ORN. LRN had a higher rate of conversion to open compared with RRN (odds ratio 1.48; 95% confidence interval 1.10–1.98; $p = 0.0087$). Conversion to open from RRN or LRN added 1.3 additional days of inpatient stay. Over the study period, RRN use increased from 4.1% to 14.8%, LRN from 20.9% to 25.6%, whereas ORN use decreased from 75% to 59.6%.

Conclusions: Minimally invasive approaches are increasingly utilized in very large renal masses. RRN has lower rates of conversion to open but produces comparable perioperative outcomes to LRN. Minimally invasive approaches have a shorter length of inpatient stay but otherwise report similar surgical margin status, readmission rates, and mortality rates compared with ORN.

Keywords: robotic surgical procedures, nephrectomy, kidney neoplasm, robotics, laparoscopy

Introduction

SINCE BEING INTRODUCED NEARLY 30 YEARS AGO, minimally invasive radical nephrectomy is now more commonly performed than open radical nephrectomy (ORN).^{1,2} Over this period, it has been demonstrated that laparoscopic radical nephrectomy (LRN) has similar oncological outcomes when compared with ORN, while providing improved perioperative morbidity, blood loss, analgesia requirements,

and hospital length of stay.^{3,4} Since the introduction of robot-assisted radical nephrectomy (RRN), multiple studies have attempted to define its role in the management of renal masses while recognizing its high hospital costs.^{5,6} Despite its increased costs without proven benefit in perioperative or oncologic outcomes, RRN continues to become increasingly utilized in the United States.⁵

There are few studies investigating trends and outcomes with minimally invasive techniques for very large renal

Departments of ¹Urology, and ²Epidemiology, University of California, Irvine, Orange, California, USA.

³Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ⁱORCID ID (<https://orcid.org/0000-0002-7708-7787>).

ⁱⁱORCID ID (<https://orcid.org/0000-0002-6755-8928>).

ⁱⁱⁱORCID ID (<https://orcid.org/0000-0002-1736-0059>).

masses >10 cm. ORN has remained the preferred approach for these very large masses given the surgical complexity and association with locally advanced or venous extension.⁷ However, given increasing utilization and comfort with laparoscopic and robotic surgery for many urologic procedures, including radical nephrectomy, we sought to determine the role of minimally invasive approaches in these large renal masses. In this study, we use the National Cancer Data Base (NCDB) to compare the perioperative outcomes of ORN, LRN, and RRN for large renal masses greater than 10 cm.

Methods

Data source

The NCDB is a facility-based, comprehensive cancer registry, established in 1989 that captures ~70% of all new cancer diagnoses across the United States. The NCDB draws data from over 1500 commission-accredited cancer programs in the United States and Puerto Rico. The database is a joint project of the American Cancer Society and the Commission on Cancer (CoC) of the American College of Surgeons. No Internal Review Board approval was required for this study.

Study population

We identified 20,790 patients ages 18 to 80 diagnosed with renal cancer from 2010 to 2015 with renal masses >10 cm. We sequentially excluded 8765 patients with stage cT3b-4 disease, 2152 patients who did not undergo radical nephrectomy, and 585 patients without defined surgical approach. The final study population included 9288 patients (Fig. 1).

Patient characteristics

Demographic and clinical characteristics such as age at diagnosis, sex, race/ethnicity, insurance status, facility type, and comorbidity were extracted from NCDB data. Tumor characteristics, including clinical and pathologic T stage, tumor grade, histology, and tumor size were recorded. Patient comorbidity was categorized as 0, 1, ≥ 2 according to NCDB Charlson/Deyo comorbidity score. Pathologic stage was determined using the American Joint Committee on Cancer Staging Manual edition in use at the time of diagnosis. Patient's surgery approach was categorized as RRN, LRN, and ORN.

Statistical analyses

Patient's demographic and clinical characteristics by surgical approach category were compared using the Chi-squared test. Adjusted odds ratios (OR), their 95% confidence intervals (CI), and *p*-values were calculated from multivariable logistic regression models to compare perioperative outcomes, such as, risk of conversion to open, surgical margin status, 30-day readmission, and 30- and 90-day mortality. A multivariate linear regression model was fitted for continuous outcome of length of inpatient stay in days. Multivariate analyses included all patient demographics, clinical, and tumor characteristics. Subset analyses within the RRN and LRN cohort were conducted in a similar manner to identify significant predictors of receipt of each surgical modality. As a sensitivity analysis, patients in each cohort were propensity score matched on a 1:1 basis, based on the previously described demographic-, clinical-, and tumor-level characteristics. Outcomes were compared using the matched sample.

FIG. 1. Consort flow diagram.

All statistical analyses were performed on SAS 9.4 (SAS Institute Cary, NC). Statistical significance was set at $p < 0.05$, using two-tailed tests.

Results

Patient characteristics

A total of 9288 patients met inclusion criteria (RRN=842, LRN=2326, ORN=6120). Of the included masses, 52.0% measured 10.1 to 12.4 cm, 26.3% measured 12.5–14.9 cm, and 21.7% measured >15.0 cm. The majority of masses were clear cell renal cell carcinoma (53.3%) (Table 1).

Trends in surgical approach

Over the 6-year study period, RRN use increased from 4.1% to 14.8%, LRN from 20.9% to 25.6%, whereas ORN use decreased from 75% to 59.6%. The percentage of nephrectomies performed open was higher at community cancer programs than at academic programs, comprehensive community cancer programs, or integrated network cancer programs (71.2% vs 67.6%, 63.8%, 62.3%, respectively). ORN use increased from 59.9% to 78% with increasing tumor size (10–12.5, 12.5–15, ≥ 15 cm), whereas RRN decreased from 10.9% to 6.2% and LRN decreased from 29.2% to 15.7% (Fig. 2).

In the subset of RRN and LRN, compared with 2010, there was an increasing likelihood to utilize RRN with each year with significance being reached from 2012 to 2015 (OR 1.57 vs 2.04 vs 2.30 vs 3.10 [2012–2015]; $p < 0.013$). Compared with community care programs, patients at integrated network cancer programs were significantly more likely to undergo RRN (OR 1.68; 95% CI 1.08–2.63). Compared with patients with comorbidity score of 0, patients with comorbidity score ≥ 2 were significantly more likely to receive RRN (OR 1.35; 95% CI 1.01–1.80). There was no difference with respect to age at diagnosis, race/ethnicity, or insurance type (Results not shown).

Conversion to open

LRN had a higher risk of conversion compared with RRN (11.4% vs 7.7%; $p = 0.0025$) (Table 2). Compared with non-Hispanic whites, non-Hispanic blacks were more likely to convert to open (OR 1.66; 95% CI 1.19–2.32). There was no significant difference between cohorts with respect to insurance type, facility type, or comorbidity score. When compared with tumor sizes 101 to 124 mm, patients with tumor size >150 mm were more likely to convert to open (OR 1.65; 95% CI 1.21–2.26). There was no significant difference with respect to tumor grade or histology (Results not shown). Overall, LRN was more likely to convert to open when compared with RRN (OR 1.48; 95% CI 1.10–1.98) on multivariate analysis, which was confirmed with the sensitivity analysis (Table 3).

Perioperative outcomes

On multivariate analysis, there was a significantly lower positive margin rate in RRN and LRN when compared with ORN (RRN: OR 0.75; 95% CI 0.56–0.99, LRN: OR 0.64; 95% CI 0.52–0.78). However, the difference in positive surgical margin rates between cohorts did not reach statistical significance on sensitivity analysis with propensity matching. When compared with ORN, RRN and LRN had no significant

difference in 30-day mortality (RRN: OR 0.86; 95% CI 0.43–1.75, LRN: OR 0.95; 95% CI 0.61–1.47) or 90-day mortality (RRN: OR 0.89; 95% CI 0.58–1.37, LRN: OR 0.81; 95% CI 0.61–1.08). There was also no difference in 30-day readmission rates when RRN and LRN were compared with ORN (RRN: OR 0.91; 95% CI 0.60–1.37, LRN: OR 0.81; 95% CI 0.61–1.07). On multivariate analysis, length of hospital stay was significantly shorter in RRN (-1.73 days ± 0.19 ; $p < 0.0001$) and LRN (-1.40 days ± 0.12 ; $p < 0.0001$) compared with ORN. Conversion to open from RRN or LRN added 1.3 additional days of inpatient stay (Table 3).

Sensitivity analysis

Following 1:1 propensity matching, 439 patients remained in each cohort. Statistical analysis with propensity matching supported the multivariate linear regression results of the study cohort for associations in conversion to open, readmission, length of stay, and mortality. Positive surgical margins did not reach significance between open and minimally invasive approaches (Table 3).

Discussion

Minimally invasive approaches for radical nephrectomy continue to grow in popularity.^{5,8,9} The cohort examined in this study not only corroborates these data, but also demonstrates a similar trend in radical nephrectomies for very large renal masses.

Few studies have specifically focused on the application of minimally invasive techniques for removal of large masses, and those exclusively investigating masses >10 cm have been limited by small cohorts.¹⁰ A recent multi-institutional retrospective analysis conducted by the ROSULA collaborative group compared the perioperative outcomes between RRN and LRN for $\geq T2$ renal masses. This was the first study to compare LRN to RRN for large masses on a large scale, however, the masses observed ranged in size from 7.4 to 10.2 cm.¹¹ Despite the increasing utilization of LRN and RRN for renal masses measuring >10 cm, perioperative outcomes have yet to be reported on the scale that they are within this study.

Between 2010 and 2015, use of LRN gradually decreased, RRN increased, and ORN remained relatively stable for renal masses of all sizes.⁵ In contrast, for masses >10 cm over the same period, LRN was still increasingly utilized. Over the study period, the proportion of large mass radical nephrectomies completed with LRN increased by 4.7%. The proportion of radical nephrectomies using RRN more than tripled during the same period, increasing by 10.7%. This may demonstrate a growing preference for RRN over LRN despite higher cost.⁵

A well-documented barrier to wide implementation of minimally invasive radical nephrectomy for larger tumors is its perceived technical difficulty, particularly by surgeons who have not received extensive training in minimally invasive techniques.^{12,13} However, robotic surgery is known to have a less significant learning curve, provide better visualization, offer superior mechanical stabilization and allow for improved ergonomics when compared with laparoscopic techniques.^{14,15}

Features unique to the robotic platform, including the use of the fourth arm and the articulation of endowrist instruments may also help with more challenging nephrectomies. These advantages may be a primary factor leading surgeons

TABLE 1. DISTRIBUTION OF PATIENT AND TUMOR CHARACTERISTICS BY SURGICAL APPROACH

	Total (N=9288)	Robotic assisted (N=842, 9.1%)	Laparoscopic (N=2326, 25.0%)	Open approach (N=6120, 65.9%)	p ^a
	n (%)	n (%)	n (%)	n (%)	
Age at diagnosis					0.0042
18–44	936 (10.1)	59 (6.3)	236 (25.2)	641 (68.5)	
45–54	2049 (22.1)	176 (8.6)	545 (26.6)	1328 (64.8)	
55–64	3086 (33.2)	298 (9.7)	721 (23.4)	2067 (67.0)	
65+	3217 (34.6)	309 (9.6)	824 (25.6)	2084 (64.8)	
Year of diagnosis					<0.0001
2010	1381 (14.9)	56 (4.1)	289 (20.9)	1036 (75.0)	
2011	1472 (15.8)	83 (5.6)	381 (25.9)	1008 (68.5)	
2012	1492 (16.1)	113 (7.6)	388 (26.0)	991 (66.4)	
2013	1524 (16.4)	144 (9.4)	384 (25.2)	996 (65.4)	
2014	1672 (18.0)	188 (11.2)	437 (26.1)	1047 (62.6)	
2015	1747 (18.8)	258 (14.8)	447 (25.6)	1042 (59.6)	
Race/ethnicity					0.376
Non-Hispanic white	7152 (77.0)	674 (9.4)	1774 (24.8)	4704 (65.8)	
Non-Hispanic black	1129 (12.2)	93 (8.2)	286 (25.3)	750 (66.4)	
Hispanic	638 (6.9)	48 (7.5)	179 (28.1)	411 (64.4)	
Asian/Pacific Islander	193 (2.9)	14 (7.3)	44 (22.8)	135 (69.9)	
Others/unknown	176 (1.9)	13 (7.4)	43 (24.4)	120 (68.2)	
Insurance					<0.0001
Private insurance	4784 (51.5)	430 (9.0)	1209 (25.3)	3145 (65.7)	
Medicare	3071 (33.1)	307 (10.0)	795 (25.9)	1969 (64.1)	
Medicaid/other government	807 (8.7)	71 (8.8)	198 (24.5)	538 (66.7)	
Not insured/unknown	626 (6.7)	34 (5.4)	124 (19.8)	468 (74.8)	
Facility type					<0.0001
Community cancer program	518 (5.6)	33 (6.4)	116 (22.4)	369 (71.2)	
Comprehensive community cancer program	3182 (34.3)	269 (8.5)	882 (27.7)	2031 (63.8)	
Academic/research program	3972 (42.8)	374 (9.4)	912 (23.0)	2686 (67.6)	
Integrated network cancer program	1159 (12.5)	139 (12.0)	298 (25.7)	722 (62.3)	
Unknown	457 (4.9)	27 (5.9)	118 (25.8)	312 (68.3)	
Comorbidity score					0.0045
0	6776 (73.0)	580 (8.6)	1687 (24.9)	4509 (66.5)	
1	1855 (20.0)	178 (9.6)	472 (25.4)	1205 (65.0)	
≥2	657 (7.1)	84 (12.8)	167 (25.4)	406 (61.8)	
Tumor grade					0.0384
I	275 (3.0)	27 (9.9)	72 (26.2)	176 (64.0)	
II	2229 (24.0)	205 (9.2)	608 (27.3)	1416 (63.5)	
III	3268 (35.2)	301 (9.2)	806 (24.7)	2161 (66.1)	
IV	1604 (17.3)	128 (8.0)	363 (22.6)	1113 (69.4)	
Unknown	1912 (20.6)	181 (9.5)	477 (24.9)	1254 (65.6)	
Histology					0.1069
Other than clear cell	4336 (46.7)	401 (9.2)	1042 (24.0)	2893 (66.7)	
Clear cell	4952 (53.3)	441 (8.9)	1284 (25.9)	3227 (65.2)	
Tumor size (mm)					<0.0001
101–124	4829 (52.0)	524 (10.9)	1411 (29.2)	2894 (59.9)	
125–149	2439 (26.3)	192 (7.9)	597 (24.5)	1650 (67.7)	
150+	2020 (21.7)	126 (6.2)	318 (15.7)	1576 (78.0)	

^ap-Value from chi-squared test to test the difference of characteristics among three approach categories.

to increasingly prefer RRN over LRN when choosing a minimally invasive technique, particularly for large masses, which are often more technically complex to remove.¹⁶ Additional possible contributing factors include growing emphasis on robotic surgery in urology residency/fellowship curriculum and patient demand.^{17–20}

Within this cohort, it is evident that ORN remains the preferred method for very large, operatively complicated mas-

ses. ORN was used with increased frequency as renal mass size increased, with 78% of masses >15 cm being removed with an open approach. While the advantages of robotic surgery may ultimately have some benefit for large, surgically complex masses, RRN for very large renal masses has only recently become more common.²¹ Possible explanations for this trend include continued advancement in robotic technology and the comfort level of robotic surgeons to perform

FIG. 2. Trends in surgical approach 2010–2015. LRN = laparoscopic radical nephrectomy; ORN=open radical nephrectomy; RRN=robot-assisted radical nephrectomy. Color images are available online.

more complex procedures.²² This may explain why academic and integrated network cancer programs were more likely to use RRN than community cancer programs.

On meta-analysis, LRN has demonstrated superiority to ORN in both overall mortality and postoperative complications, but only for masses <7 cm.²³ Similarly, in more limited studies, RRN has been shown to have equivalent perioper-

ative outcomes and postoperative complication rates to LRN.^{6,24} In our study of large masses, LRN and RRN were statistically equivalent to ORN for all observed perioperative outcomes with the exception of length of hospital stay, which was significantly shorter for both LRN and RRN. Length of stay for LRN and RRN was comparable. These results suggest that both LRN and RRN can be successfully employed for selected renal masses >10 cm, while allotting the patient shorter recovery times.

The cost of procedures is often discussed as a shortcoming of RRN when compared with LRN, given otherwise similar perioperative results. However, conversion to ORN from a minimally invasive radical nephrectomy has rarely been analyzed on a significant scale.^{5,25} Helmers and colleagues found that in a single institution cohort of 319 patients, with masses of a median diameter of 5.5 cm, in years 2010 to 2014, conversion to another approach was significantly higher for RRN than LRN (11.1% vs 1.0%, $p < 0.001$), although the authors noted that the majority of RRN conversions occurred early in the surgeon's robotic surgery experience.⁶

A recent meta-analysis of perioperative outcomes for radical nephrectomy from Li and colleagues (mass median diameter 5.6–8.7 cm) demonstrated similar rates of conversion when comparing RRN and LRN (3.88% vs 1.60%, $p = 0.16$).²⁶ In this study, a contradictory observation was made that conversion to open was more likely for LRN than RRN (11.4% vs 7.7%; $p = 0.0025$). The cohort of surgeons reported in this study may have been adequately robust and diverse to account for a small number of RRN conversions

TABLE 2. DISTRIBUTION OF OUTCOMES BY SURGICAL APPROACH

	Total (N=9288)	Robotic assisted (N=842, 9.1%)	Laparoscopic (N=2326, 25.0%)	Open approach (N=6120, 65.9%)	
	n (%)	n (%)	n (%)	n (%)	p ^a
Conversion to open approach					0.0025
No	2837 (89.6)	777 (92.3)	2060 (88.6)	—	
Yes	331 (10.4)	65 (7.7)	266 (11.4)	—	
Surgical margin ^b					<0.0001
No residual tumor	8243 (90.3)	770 (92.3)	2145 (93.6)	5328 (88.7)	
Yes	887 (9.7)	64 (7.7)	146 (6.4)	677 (11.4)	
30-Day readmission ^b					0.1083
No	8941 (96.5)	814 (96.8)	2257 (97.1)	5870 (96.2)	
Yes	326 (3.5)	27 (3.2)	67 (2.9)	232 (3.8)	
30-Day mortality ^b					0.5721
Patient alive, or died more than 30 days after surgery performed	8977 (98.7)	814 (98.9)	2236 (98.8)	5927 (98.6)	
Patient died 30 or fewer days after surgery performed	122 (1.3)	9 (1.1)	27 (1.2)	86 (1.4)	
90-Day mortality ^b					0.0054
Patient alive, or died more than 90 days after surgery performed	8578 (96.0)	784 (96.8)	2157 (97.0)	5637 (95.5)	
Patient died 90 or fewer days after surgery performed	357 (4.0)	26 (3.2)	67 (3.0)	264 (4.5)	
Surgical inpatient stay (days from surgery), mean ± SD	4.9 ± 5.1	3.6 ± 3.5	3.9 ± 4.9	5.5 ± 5.2	<0.0001

^ap-Value from chi-squared test or analysis of variance test to test the difference of distribution of outcome among three approach categories.

^bA small percentage of missing due to unknown information.

SD=standard deviation.

TABLE 3. COMPARISON OF PERIOPERATIVE OUTCOMES

	<i>Multivariate cohort (N=9288)</i>				<i>Propensity score matched sample (N=1317)</i>			
	<i>Adjusted odds ratio</i>	<i>95% Confidence interval</i>		<i>p^a</i>	<i>Odds ratio</i>	<i>95% Confidence interval</i>		<i>p^a</i>
Surgical margin positive								
Open approach	1.00	—	—		1.00	—	—	
Robot assisted	0.75	0.56	0.99	0.0443	0.74	0.47	1.18	0.2079
Laparoscopic	0.64	0.52	0.78	<0.0001	0.64	0.39	1.03	0.0663
30-Day readmission								
Open approach	1.00	—	—		1.00	—	—	
Robot assisted	0.91	0.60	1.37	0.6418	1.18	0.53	2.67	0.6835
Laparoscopic	0.81	0.61	1.07	0.143	1.38	0.63	3.03	0.4276
30-Day mortality								
Open approach	1.00	—	—		1.00	—	—	
Robot assisted	0.86	0.43	1.75	0.6809	1.26	0.34	4.72	0.7331
Laparoscopic	0.95	0.61	1.47	0.8033	1.54	0.43	5.48	0.5086
90-Day mortality								
Open approach	1.00	—	—		1.00	—	—	
Robot assisted	0.89	0.58	1.37	0.5943	1.20	0.57	2.53	0.6303
Laparoscopic	0.81	0.61	1.08	0.145	0.76	0.33	1.75	0.5193
Conversion to open ^b								
Robot assisted	1.00	—	—		1.00	—	—	
Laparoscopic	1.48	1.10	1.98	0.0087	1.82	1.13	2.93	0.0143
	<i>Estimate</i>	<i>Standard error</i>			<i>Estimate</i>	<i>Standard error</i>		
Surgical inpatient stay (days from surgery)								
Open approach	1.00	—	—		1.00	—	—	
Robotic assisted	-1.73	0.19	<0.0001		-1.80	0.28	<0.0001	
Laparoscopic	-1.40	0.12	<0.0001		-1.82	0.28	<0.0001	

^a*p*-Value from logistic regression or linear regression models for the odds ratio or parameter estimate. Analysis for multivariate cohort adjusted for all demographic and clinical characteristics in Table 1.

^bAmong subset of robot-assisted or laparoscopic approaches.

attributable to novice robotic surgeons overcoming the learning curve of robotic surgery. It is also possible that surgeons choosing LRN may be more prone to elect to convert to ORN than those with a robotic setup. However, with advancing robotic technology, RRN may offer particular benefit for large masses, leading to the trend observed in this study and explaining the difference in results from studies of masses of smaller median diameter. In other surgical fields, laparoscopic surgery has also been shown to have a greater risk of conversion than robotic surgery and conversion has been shown to substantially increase the cost of surgery.^{27,28} Increased cost associated with conversion is partially due to the associated increased length of hospital stay.²⁹ On average, conversion to open resulted in an additional 1.3-day hospital stay, which was similar to the average length of stay for ORN. There is evidence to suggest that the cost discrepancy between RRN and LRN may not be as significant as previously thought.^{6,26} Future cost analysis could further justify these findings by determining if the discrepancy in conversion rate between LRN and RRN in large renal masses specifically is considerable enough to offset the higher base cost of RRN.

Limitations

Retrospective studies that utilize large national databases offer robust sets of real-world data but are inherently limited in several ways.³⁰ While randomized study designs would be

more ideal to limit selection bias, it is technically difficult and expensive to conduct studies for relatively rare, high-stakes treatments. In this study, several specific shortcomings should be appreciated. First, no cost-based analysis was conducted as a part of this study, which has been one of the key points of differentiation when comparing LRN to RRN in recent literature.^{5,6} Additionally, the NCDB did not allow for the analysis of certain parameters that have been reported by other studies comparing radical nephrectomy approaches, including nephrometry scores, reason for conversion, blood loss volumes, and operation times.^{6,11} The NCDB also lacks granular details about tumor complexity. Ideally, information on specific surgical technique (e.g., hand-assisted laparoscopy), tumor characteristics beyond basic staging, and long-term oncologic outcomes would allow surgical approaches to be compared with a more complete clinical picture. Due to the inherent limitations of this study, all statistically derived conclusions require further study for confirmation. Despite these clear limitations, the study offers valuable insight into the perioperative outcomes of a rarely examined subset of renal masses.

Conclusion

Minimally invasive approaches are increasingly utilized for very large renal masses. In selected patients, LRN and RRN can be performed as safely as ORN for renal masses

>10 cm. After adjusting for covariates, RRN has lower rates of conversion to open but produces comparable perioperative outcomes to LRN. LRN and RRN both resulted in significantly shorter length of inpatient hospital stay but are otherwise equivalent to ORN for all other perioperative outcomes. RRN may offer technical advantages that allow it to be more easily implemented for very large, technically complex, renal masses than LRN, while still offering the benefits of minimally invasive surgery.

Authors' Contributions

F.V.C., J.C., A.Zr., H.A.-C., and G.E.G collected initial data from NCDB. L.W.G., F.V.C., J.C., E.M.U., J.P.S., K.K.B., and G.E.G., collaborated on study design. J.C., A.Z., and H.A.-C. completed statistical analysis. L.W.G., F.V.C., J.C., A.Z., H.A.-C., E.M.U., J.P.S., K.K.B., and G.E.G. interpreted final data. L.W.G., F.V.C., J.C., and G.E.G. created tables and figures. L.W.G., F.V.C., J.C., and G.E.G. drafted article. L.W.G., J.C., and G.E.G edited/revised article. All authors approved the final article.

Acknowledgments

The data used in the study are derived from a deidentified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

No funding was received for this article.

References

1. Clayman RV, Kavoussi LR, Soper NJ, et al. Laparoscopic nephrectomy: Initial case report. *J Urol* 1991;146:278–282.
2. Poon SA, Silberstein JL, Chen LY, Ehdaie B, Kim PH, Russo P. Trends in partial and radical nephrectomy: An analysis of case logs from certifying urologists. *J Urol* 2013;190:464–469.
3. Dunn MD, Portis AJ, Shalhav AL, et al. Laparoscopic versus open radical nephrectomy: A 9-year experience. *J Urol* 2000;164:1153–1159.
4. Permpongkosol S, Chan DY, Link RE, et al. Long-term survival analysis after laparoscopic radical nephrectomy. *J Urol* 2005;174:1222–1225.
5. Jeong IG, Khandwala YS, Kim JH, et al. Association of robotic-assisted vs laparoscopic radical nephrectomy with perioperative outcomes and health care costs, 2003 to 2015. *JAMA* 2017;318:1561–1568.
6. Helmers MR, Ball MW, Gorin M, Pierorazio PM, Allaf ME. Robotic versus laparoscopic radical nephrectomy: Comparative analysis and cost considerations. *Can J Urol* 2016;23:8435–8440.
7. Berger AD, Kanofsky JA, O'Malley RL, et al. Transperitoneal laparoscopic radical nephrectomy for large (more than 7cm) renal masses. *Urology* 2008;71:421–424.
8. Liu JJ, Leppert JT, Maxwell BG, Panousis P, Chung BI. Trends and perioperative outcomes for laparoscopic and robotic nephrectomy using the National Surgical Quality Improvement Program (NSQIP) database. *Urol Oncol* 2014;32:473–479.
9. Xia L, Talwar R, Taylor BL, et al. National trends and disparities of minimally invasive surgery for localized renal cancer, 2010 to 2015. *Urol Oncol* 2019;37:182.e17–e182.e27.
10. Abaza R, Gerhard RS, Martinez O. Robotic radical nephrectomy for massive renal tumors. *J Laparoendosc Adv Surg Tech A* 2020;30:196–200.
11. Anele UA, Marchioni M, Yang B, et al. Robotic versus laparoscopic radical nephrectomy: A large multi-institutional analysis (ROSULA Collaborative Group). *World J Urol* 2019;37:2439–2450.
12. Hemal AK, Kumar A, Kumar R, Wadhwa P, Seth A, Gupta NP. Laparoscopic versus open radical nephrectomy for large renal tumors: A long-term prospective comparison. *J Urol* 2007;177:862–866.
13. Fenn NJ, Gill IS. The expanding indications for laparoscopic radical nephrectomy. *BJU Int* 2004;94:761–765.
14. Herron DM, Marohn M; SAGES-MIRA Robotic Surgery Consensus Group. A consensus document on robotic surgery. *Surg Endosc* 2008;22:313–312.
15. Pal RP, Koupparis AJ. Expanding the indications of robotic surgery in urology: A systematic review of the literature. *Arab J Urol* 2018;16:270–284.
16. Simhan J, Smaldone MC, Tsai KJ, et al. Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. *Eur Urol* 2011;60:724–730.
17. Lovegrove CE, Elhage O, Khan MS, et al. Training modalities in robot-assisted urologic surgery: A systematic review. *Eur Urol Focus* 2017;3:102–116.
18. Stegemann AP, Ahmed K, Syed JR, et al. Fundamental skills of robotic surgery: A multi-institutional randomized controlled trial for validation of a simulation-based curriculum. *Urology* 2013;81:767–774.
19. Thomas D, Medoff B, Anger J, Chughtai B. Direct-to-consumer advertising for robotic surgery. *J Robot Surg* 2020;14:17–20.
20. Zorn KC, Gautam G, Shalhav AL, et al. Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: Recommendations of the society of urologic robotic surgeons. *J Urol* 2009;182:1126–1132.
21. Eskicorapci SY, Teber D, Schulze M, Ates M, Stock C, Rassweiler JJ. Laparoscopic radical nephrectomy: The new gold standard surgical treatment for localized renal cell carcinoma. *ScientificWorldJournal* 2007;7:825–836.
22. Navaratnam A, Abdul-Muhsin H, Humphreys M. Updates in urologic robot assisted surgery. *F1000Res* 2018;7:F1000 Faculty Rev-1948.
23. Liu G, Ma Y, Wang S, Han X, Gao D. Laparoscopic versus open radical nephrectomy for renal cell carcinoma: A systematic review and meta-analysis. *Transl Oncol* 2017;10:501–510.
24. Boger M, Lucas SM, Popp SC, Gardner TA, Sundaram CP. Comparison of robot-assisted nephrectomy with laparoscopic and hand-assisted laparoscopic nephrectomy. *JSLS* 2010;14:374–380.
25. Gershman B, Bukavina L, Chen Z, et al. The association of robot-assisted versus pure laparoscopic radical nephrectomy with perioperative outcomes and hospital costs. *Eur Urol Focus* 2020;6:305–312.

26. Li J, Peng L, Cao D, et al. Comparison of perioperative outcomes of robot-assisted vs. laparoscopic radical nephrectomy: A systematic review and meta-analysis. *Front Oncol* 2020;10:551052.
27. Cleary RK, Mullard AJ, Ferraro J, Regenbogen SE. The cost of conversion in robotic and laparoscopic colorectal surgery. *Surg Endosc* 2018;32:1515–1524.
28. Bhama AR, Obias V, Welch KB, Vandewarker JF, Cleary RK. A comparison of laparoscopic and robotic colorectal surgery outcomes using the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database. *Surg Endosc* 2016;30:1576–1584.
29. Clinical Outcomes of Surgical Therapy Study Group, Nelson H, Sargent DJ, et al. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med* 2004;350:2050–2059.
30. Alluri RK, Leland H, Heckmann N. Surgical research using national databases. *Ann Transl Med* 2016;4:393.

Address correspondence to:

Greg E. Gin, MD

Department of Urology

University of California, Irvine

333 The City Boulevard W., Suite 2100

Orange, CA 92868

USA

E-mail: ggin1@hs.uci.edu

Abbreviations Used

CI = confidence intervals

LRN = laparoscopic radical nephrectomy

NCDB = National Cancer Data Base

OR = odds ratios

ORN = open radical nephrectomy

RRN = robot-assisted radical nephrectomy